FDA Approved: BYETTA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approves a supplemental application for BYETTA (exenatide) from AstraZeneca Pharmaceuticals LP, resulting in an update to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BYETTA (Exenatide)

Snippet

SUPPL AP for BYETTA (EXENATIDE)